Abstract: The present invention is directed to fusion proteins having an IL-21 cytokine portion and an anti-CD20 antibody portion, and methods of using such fusion proteins. The invention also provides pharmaceutical compositions and kits utilizing the IL-21-anti-CD20 fusion proteins. In particular, the methods, kits and compositions of the invention are useful in the treatment of cancer and autoimmune diseases.

Abstract: Modified glucagon peptides are disclosed having enhanced potency at the glucagon receptor relative to native glucagon. Further modification of the glucagon peptides by forming lactam bridges or the substitution of the terminal carboxylic acid with an amide group produces peptides exhibiting glucagon/GLP-1 receptor co-agonist activity. The solubility and stability of these high potency glucagon analogs can be further improved by modification of the polypeptides by pegylation, substitution of carboxy terminal amino acids, or the addition of a carboxy terminal peptide selected from the group consisting of SEQ ID NO: 26 (GPSSGAPPPS), SEQ ID NO: 27 (KRNRNNIA) and SEQ ID NO: 28 (KRNR).

Abstract: The present application discloses a chromatographic process for separating protein components of a protein-containing solution, the solution comprising an insulin peptide and one or more di- or polyvalent metal ions, the insulin peptide being capable of self-association and/or structural change in the presence of di- or polyvalent metal ions, the process comprising the steps of: a) applying the protein-containing solution to a column of a chromatographic solid phase material, wherein the loading of the insulin peptide is at least 6.0 g per liter of column volume (g/LCV); and b) eluting the insulin peptide from the solid phase material using an eluent having a pH of at the most 8.5; and collecting a pool of the insulin peptide corresponding to at least 75% by weight of the insulin peptide applied to the column in step (a).

Abstract: Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the use of modified messenger RNAs, and are useful to treat or prevent diseases, disorders or conditions, or to improve a subject's heath or wellbeing.

Abstract: The present invention provides variant activin IIB soluble receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the variant polypeptides and proteins. Compositions and methods for treating muscle-wasting and other diseases and disorders are also provided.

Abstract: The present invention provides an intraceptor that interacts with and decreases activity of with VEGF and/or a VEGFR for the treatment of angiogenesis-related conditions. The present invention further provides pharmaceutical compositions, and methods of use thereof, for the treatment and prevention of an angiogenesis-related condition using said intraceptors. The invention further provides for nucleic acids encoding said intraceptors.

Abstract: Disclosed is a novel means that enables mass production of highly safe fibrinogen at low cost. The transgenic silkworm of the present invention expresses the fibrinogen subunit A?, B? and ? chains in the silk gland cells and produces fibrinogen having coagulation activity in the cocoon filament. Preferably, the transgenic silkworm expresses the subunits in the middle silk gland cells and produces fibrinogen in the sericin layer of the cocoon filament. By recovering fibrinogen from the cocoon of the transgenic silkworm of the present invention, highly safe fibrinogen can be mass-produced at low cost.

Abstract: There is provided a nucleic acid molecule comprising a nucleotide sequence encoding for a functional factor VIII protein, wherein the portion of the nucleotide sequence encoding for the B domain of the factor VIII protein is between 90 and 111 nucleotides in length and encodes for an amino acid sequence comprising a sequence having at least 85% identity to SEQ ID NO: 4 and which comprises six asparagine residues. Also provided is a functional factor VIII protein, a vector comprising the above nucleic acid molecule, a host cell, a transgenic animal, a method of treating hemophilia, e.g. hemophilia A, and a method for the preparation of a parvoviral gene delivery vector.

Abstract: The invention relates to hemostatic compositions and methods for promoting hemostasis. The invention also relates to hemostatic compositions and methods for promoting wound healing. In various embodiments, the hemostatic compositions comprise crosslinkable collagen molecules having a porosity controlled by the ratio of weight percent collagen solids to weight percent crosslinker when crosslinking the collagen. In other embodiments, the hemostatic compositions comprise crosslinkable collagen molecules having a porosity controlled by the temperature and rate of freezing when drying the composition during fabrication. In some embodiments, the compositions contain additional agents, including biological agents.

Abstract: The invention provides novel scaffold proteins for the display of peptides such as peptide aptamers. The novel scaffold proteins are modifications of Stefin A or STM (a variant of Stefin A) and are useful as scaffold proteins and as display systems.

Abstract: A process for purification of a fragment antibody from a culture medium also comprising at least one impurity is provided. The purification is carried out after the pH of the culture medium has been reduced to a pH at which the fragment antibody is soluble, but one or more of the impurities are insoluble. A process for the preparation of a fragment antibody employing such a purification process is also provided.

Abstract: The invention relates to antibodies and subsequences thereof that specifically bind to poxvirus B5R envelope protein, antibodies and subsequences thereof that specifically bind to poxvirus H3L envelope protein, and combinations thereof.

Abstract: The present invention provides fully human antibodies that bind to respiratory syncytial virus F protein, compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for preventing fusion of the virus with the cell membrane and preventing cell to cell spread of the virus, thereby providing a means of preventing the infection, or treating a patient suffering from the infection and ameliorating one or more symptoms or complications associated with the viral infection. The antibodies may also be useful for diagnosis of an infection by RSV.

Abstract: Methods for producing recombinant cell populations are disclosed. The disclosed methods may be used to produce therapeutic polyclonal proteins.

Abstract: The present invention relates to an antibody which specifically binds to unprocessed and/or partially processed neurotoxin polypeptide or an antibody which specifically binds an epitope consisting of a peptide having an amino acid sequence as shown in any one of SEQ ID NOs: 1 to 16 and to methods for the manufacture of such antibodies. Moreover, the present invention relates to a composition comprising processed neurotoxin polypeptide free of unprocessed or partially processed neurotoxin polypeptide and a method for manufacturing said neurotoxin polypeptide based on the antibodies of the invention. The present invention also relates to the use of the aforementioned antibody for separating processed neurotoxin polypeptides from unprocessed or partially processed neurotoxin polypeptides or for determining unprocessed or partially processed neurotoxin polypeptides. The present invention relates to a method for the manufacture of a medicament.

Abstract: The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.

Abstract: The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanized antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.

Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis and prognosis of acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer or pancreatic cancer, for monitoring the effectiveness of acute myeloid leukemia (AML), B-cell chronic lymphocytic leukemia, breast cancer, colorectal cancer, kidney cancer, head and neck cancer, lung cancer, ovarian cancer or pancreatic cancer treatment, and for drug development. The present invention also provides methods and compositions for depletion of immune cells to treat inflammatory diseases.

Abstract: This invention concerns affinity tools for oligomeric forms of tau protein. It relates to the field of neurodegeneration, more particularly to the field of tau-related diseases and tauopathy. The invention provides novel tau antibodies and antibody fragments, nucleic acids encoding such antibodies and antibody fragments, cell lines producing such antibodies and antibody fragments, antibody compositions, and kits for the detection of aggregated tau and for the diagnosis of diseases involving aggregated tau. The invention further provides methods for the detection of aggregated tau, for the diagnosis of diseases involving aggregated tau, and for the identification of compositions interfering with the formation and/or stability of tau aggregates.

Abstract: The present disclosure provides methods of treating a tauopathy, involving administering an anti-Tau antibody. The present disclosure also provides anti-Tau antibodies, and formulations comprising same, for use in the methods.

Abstract: The present invention provides anti-nerve growth factor (NGF) antibodies that contain an IgG4 constant region comprising a stabilizing hinge region mutation and wherein the antibodies exhibit an unexpectedly long serum half life in cynomolgus monkeys. Pharmaceutical compositions comprising the anti-NGF antibodies, nucleic acids encoding the NGF antibodies, host cells for expressing the NGF antibodies and methods of using the antibodies for treating NGF-related diseases or conditions are also provided.

Abstract: The invention concerns antibodies directed against CD127, I.e. the alpha chain of the receptor for interleukin7 (IL-7), especially the receptor for human IL-7 expressed on human cells (designated human IL-7R alpha or IL-7Ra) or the TSLP receptor. The antibodies of the invention have cytotoxic activity against CD127 positive cells. The invention also relates to the use of these antibodies in order to deplete subpopulations of T lymphocytes as a result of cytotoxic action of the antibodies, through ADCC and optionally through CDC. Accordingly the invention concerns the use of the antibodies in the treatment of transplant rejection, autoimmune diseases, allergic diseases, lymphoma or cancer when these pathologies are associated with CD127 positive cells.

Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.

Abstract: Proteins that bind IL-1? and IL-1? are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1? and IL-1? in cells, tissues, samples, and compositions.

Abstract: The present invention relates to methods of treating proliferative disorders, particularly immunoproliferative and autoimmune disorders, and methods of producing antibodies which bind NK cell receptors for use in therapeutic strategies for treating such disorders, particularly to deplete cells involved in the immunoproliferative pathology.

Abstract: Methods are provided for treating metastatic cancer in patients having metastatic cancer or for preventing metastasis in cancer patients at risk for metastasis comprising administering to the patient an antibody to B7x, or an active antibody fragment that binds B7x, in an amount effective to treat or prevent metastasis.

Abstract: The present disclosure provides methods useful for prolonging the survival of an allograft organ in a recipient mammal. The methods include administration of an anti-CD200 antibody or a CD200-binding fragment of the antibody. The disclosure also provides biomarkers, a change in one or more of which indicates that an anti-CD200 antibody has produced a desired immunomodulatory effect in a mammal. Also featured are pharmaceutical compositions, kits, and solutions that contain at least one anti-CD200 antibody and are useful in the methods described herein.

Abstract: The present invention relates to a method of controlling quality and quantity of posttranslational modification of a recombinantly produced polypeptide/protein (glycoprotein), wherein the posttranslational modification affects the glycosylation profile and/or the acidic variants profile, as manifested in CEX profiles, wherein the polypeptide/protein (glycoprotein) production is in eukaryotic host cells, the method comprising the following steps: a) cultivating the eukaryotic cells in a suitable medium under conditions which allow the expression of the polypeptide/protein, wherein the content of the dissolved CO2 (pCO2) in the medium is at a first value during the initial growth phase of the eukaryotic cells, allowing the eukaryotic cells to grow, and b) increasing or decreasing the content of the dissolved CO2 (pCO2) in the medium during the production phase of the eukaryotic cells to a second value.

Abstract: Methods of using CD37 agents, including, but not limited to, antibodies and immunoconjugates, that bind to CD37 to deplete B-cells (e.g., non-cancerous B-cells) and methods of treating autoimmune and inflammatory diseases are further provided.

Abstract: Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin ?-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.

Abstract: The purpose of the present invention is to provide an osteogenesis promoter for directly promoting osteogenesis by osteoblasts, and an agent for preventing and treating bone disease. The present invention is characterized in that a binding inhibitor substance of semaphorin 4D and plexin B1 is used. For the binding inhibitor substance, suitable examples include anti-semaphorin 4D antibody, anti-plexin B1 antibody, and protein comprising the extracellular domain of plexin B1.

Abstract: This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.

Abstract: A method for treating cancer includes administering to a subject in need thereof an antibody against a transmembrane and coiled-coil domains protein 3 (TMCC3), wherein the antibody binds to an epitope in an extracellular domain of TMCC3. The antibody binds to an epitope in an intercoil domain of TMCC3. A method of diagnosing or assessing a cancer condition includes assessing a level of expression or activity of a transmembrane and coiled-coil domains protein 3 (TMCC3) in a sample, wherein an increase in the level of expression of activity of TMCC3 as compared to a standard indicates the presence of cancer stem cells in the sample.

Abstract: The invention is directed to a bispecific chimeric antigen receptor, comprising: (a) at least two antigen-specific targeting regions; (b) an extracellular spacer domain; (c) a transmembrane domain; (d) at least one co-stimulatory domain; and (e) an intracellular signaling domain, wherein each antigen-specific targeting region comprises an antigen-specific single chain Fv (scFv) fragment, and binds a different antigen, and wherein the bispecific chimeric antigen receptor is co-expressed with a therapeutic control. The invention also provides methods and uses of the bispecific chimeric antigen receptors.

Abstract: This invention concerns the first environmentally benign heterogeneous modification of polysaccharide-based material in native solid state by thiol-ene “click chemistry”. The direct reaction of a thiol with an un-activated double or triple bond by thiol-ene and thiol-enyne click modification is thermally or photochemically catalyzed and is completely metal-free and allows for a highly modular approach to modifications of fibers and fiber-based materials.

Abstract: A process for dissolving modified cellulose includes contacting modified cellulose solution with at least one non-solvent to form a plurality of modified cellulose particles.

Abstract: A process for dissolving modified cellulose includes contacting modified cellulose solution with at least one neutralizing agent to form a plurality of modified cellulose particles.

Abstract: This invention relates to a field of pharmaceutical chemistry, relates to a process of extracting high water soluble polysaccharides from higher plants or fungi. The present invention discloses a process of extracting higher plants and fungi polysaccharides based on a microwave chemistry method, comprising: putting the residue or pulverized higher plants and fungi after being degreased by an organic solvent into a microwave reaction chamber to react with an acid solution; and then distilling to remove excess acid or washing with organic solvent to remove the acid; adding water solution for extraction, subjecting the extracting solution after concentration to alcohol precipitation, separating precipitates aka polysaccharides therefrom. The present invention has significant advantages like fast processing rate, high polysaccharides yield, low organic acid consumption and efficient and easy to recycle, low water consumption, low power consumption, etc.

Abstract: This invention relates to an extraction process of brown algae polysaccharides in a field of pharmaceutical chemistry. This invention particularly discloses a process of extracting brown algae polysaccharides based on a microwave chemistry method and brown algae polysaccharides obtained by said process. The process of the invention comprises: 1) putting pulverized brown algae powder into a microwave reaction chamber, adding acid solution to conduct reaction; optionally concentrating the mixer, and then washing with organic solvent to remove excess acid; conducting grading alcohol precipitation after water extract to obtain mannuronic acid rich fragment (M rich) algin, fucoidan and/or laminaran respectively; and adding an alkali solution to the brown algae residue to conduct alkaline digestion, filtering the residue off, adjusting pH of the filtrate to neutral, conducting alcohol precipitation to obtain guluronic acid rich fragment (G rich) algin precipitates.

Abstract: Provided is a method of producing a stabilized polymer in which inhibition of polymerization of a monomer having an ethylenically unsaturated bond is suppressed even when a specific phenolic antioxidant is added before or during the polymerization of the monomer.

Abstract: The present invention relates to a polymerization inhibitor composition and a method of inhibiting polymerization of distillable monomers in liquid and evaporated/condensed phases with the polymerization inhibitor composition. The polymerization inhibitor composition is useful for inhibiting polymerization of the distillable monomers during manufacture, purification (e.g., distillation), handling, and storage thereof.

Abstract: A process for oligomerization of an olefinic compound for producing an oligomeric product is carried out in the presence of an activated catalyst, a non-metal oxygen containing additive and optionally a zinc compound. The oligomerization catalyst is an activated catalyst, which is provided by combining a source of chromium, a ligating compound, and a catalyst activator or combination of catalyst activators. The non-metal oxygen containing additive is present in an amount such that the ratio of the molar amount of the non-metal oxygen containing additive to the molar amount of chromium in the source of chromium per 106 g/g Cr productivity is between 0.01 and 400.

Abstract: An object of the present invention is to provide a method for producing water absorbent resin powder in which permeability potential (SFC) is improved while a water absorbing rate (FSR) is being kept. The method is a method for producing water absorbent polyacrylic acid (salt) resin powder including the steps of: (i) polymerizing an acrylic acid (salt) monomer aqueous solution; (ii) during or after the step of (i), performing gel grinding of a hydrogel crosslinked polymer obtained by the polymerization, wherein the hydrogel crosslinked polymer has resin solid content of 10 wt % to 80 wt %, and the gel grinding is carried out with gel grinding energy (GGE) of 18 [J/g] to 60 [J/g]; (iii) drying a particulate hydrogel crosslinked polymer obtained by the gel grinding, wherein the drying is performed at 150° C. to 250° C.; and (iv) carrying out a surface treatment to the particulate hydrogel crosslinked polymer thus dried.

Abstract: Catalyst deactivating agents and compositions containing catalyst deactivating agents are disclosed. These catalyst deactivating agents can be used in methods of controlling polymerization reactions, methods of terminating polymerization reactions, methods of operating polymerization reactors, and methods of transitioning between catalyst systems.

Abstract: A plasma treatment method that includes providing treatment chamber including an intermediate heating volume and an interior treatment volume. The interior treatment volume contains an electrode assembly for generating a plasma and the intermediate heating volume heats the interior treatment volume. A work piece is traversed through the treatment chamber. A process gas is introduced to the interior treatment volume of the treatment chamber. A plasma is formed with the electrode assembly from the process gas, wherein a reactive species of the plasma is accelerated towards the fiber tow by flow vortices produced in the interior treatment volume by the electrode assembly.

Abstract: The present invention relates to a process for the preparation of ethylene polymers using a number of reactors arranged in series comprising the steps in which a) ethylene, a diluent, a catalyst, a co-catalyst and optionally comonomers and hydrogen are introduced into a first reactor, b) polymerization of ethylene and optionally comonomers is carried out in the reaction mixture of said first reactor to make ethylene polymers, c) reaction mixture is discharged from said first reactor, d) said reaction mixture and fresh ethylene and optionally comonomers and hydrogen are introduced into the consecutive reactor to make additional ethylene polymers, e) said reaction mixture is discharged from said consecutive reactor and introduced into the further consecutive reactor, if any, with fresh ethylene and optionally comonomers and hydrogen to make additional ethylene polymers, steps c) and d) are repeated until the last reactor of the series, f) reaction mixture is discharged from last reactor of the series and ethyl

Abstract: Catalyst and solid component of catalyst for the (co)polymerization of ethylene, comprising titanium, magnesium, chlorine, a protic organo-oxygenated compound Dp and a neutral aprotic electron-donor compound D, in the following molar ranges: Mg/Ti=1.0-50; D/Ti=1.0-15; Cl/Ti=6.0-100; Dp/D=0.05-3; and a process for obtaining said component.

Abstract: An object of the present invention is to provide a rubber composition for a tire, capable of achieving both good rolling resistance properties and good wear resistance in a sufficiently compatible manner when the rubber composition is applied to a component member of a tire. Specifically, the present invention provides a rubber composition comprising a rubber composition and hydrated silica, wherein “CTAB” (m2/g) as specific surface area by cetyltrimethylammonium bromide adsorption and “IB” as ink bottle-shaped micropore index, of the hydrated silica, satisfy a specific relationship and “weight loss on ignition” as weight loss when the hydrate silicate is heated at 750° C. for 3 hours and “weight loss on heating” as weight loss when the hydrate silicate is heated at 105° C. for 2 hours satisfy a specific relationship.

Abstract: Process for the preparation of diene polymers or random vinyl arene-diene copolymers which comprises (co)polymerizing, anionically, in the presence of at least one hydrocarbon solvent, at least one conjugated diene monomer and optionally at least one vinyl arene, in the presence of at least one lithium-based initiator, at least one aprotic polar compound, and at least one compound containing one or more functional groups of the acetylenic type. Said process allows diene polymers or random vinyl arene-diene copolymers to be obtained, which can be advantageously used in the production of tires, in particular in the production of tire treads. The diene polymers or the random vinyl arene-diene copolymers obtained through said process can also be used for the modification of plastic materials [for example, for obtaining high impact polystyrene (HIPS)].

Abstract: Provided are an olefin composition, filler and an optoelectronic device. One illustrative olefin composition may be effectively used as a filling material for various optoelectronic devices.